eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

3/2020
vol. 12
 
Share:
Share:
more
 
 
abstract:
Original paper

High-dose-rate brachytherapy of primary cutaneous B-cell lymphoma: the first reported case series

Artur Chyrek
1
,
Grzegorz Bielęda
2, 3
,
Wojciech Burchardt
1
,
Adam Chicheł
1

1.
Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland
2.
Electroradiology Department, University of Medical Sciences, Poznan, Poland
3.
Medical Physics Department, Greater Poland Cancer Centre, Poznan, Poland
J Contemp Brachytherapy 2020; 12, 3: 241–247
Online publish date: 2020/06/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Cutaneous B-cell lymphomas (CBCLs) are a rare group of diseases. External beam radiation therapy is recommended to treat CBCLs in all subtypes for locally advanced cases. However, there are no reports on high-dose-rate brachytherapy (HDR-BT) exclusively dedicated to CBCLs. The purpose of this paper was to report the first case series of CBCLs treated with HDR-BT.

Material and methods
Seven patients were treated between 2011 and 2019, with 12 skin lesions histopathologically proven as CBCLs. There were four T1a and eight T2a lesions. HDR-BT was prescribed as the first-line treatment for all cases, as the second-line treatment for recurrences after surgical failure for 4 patients, and as an adjuvant treatment for 1 case. The median total dose was 36 Gy (range, 30-40 Gy) in 10 fractions (range, 6-10 fractions), with a median overall treatment time of 11 days (range, 4-11 days). Treatment toxicity was assessed accordingly to the RTOG scale.

Results
The mean follow-up was 41 months. Local control was 100%. The rates of early toxicity were as follows: erythema (G1) – 33%, patchy epidermal desquamation (G2) – 25%, confluent epidermal desquamation (G3) – 25%, and minor bleeding (G4) – 17%. The reported rates of late toxicity included slight depigmentation (G1) – 59%, small telangiectasia (G2) – 8%, massive telangiectasia (G3) – 25%, and small ulceration (G4) in one site irradiated interstitially (8%).

Conclusions
HDR-BT allows for achieving high local control of CBCLs with relatively low-late toxicity in the form of skin discoloration in most patients.

keywords:

B-cell lymphomas, skin, HDR, brachytherapy

 
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe